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Tenoxicam, a piroxicam analogue, is an NSAID (Non-Steroid
Antinflamatory Drug). It is used in the symptomatic management of
musculoskeletal and joint disorders such as osteoarthritis and
rheumatoid arthritis, and also in the short-term management of soft-
tissue injury. Its quantitative determination in pharmaceutical
formulations is important to guarantee the desired therapeutic effects.
The objective of this research was to develop, validate and compare
spectrophotometric and chromatographic methods in the quantitative
determination of tenoxicam in tablet preparations. In this work, tablets
containing 20.0 mg of tenoxicam from different origins were analyzed.
The spectrophotometric method was validated using 0.1 mol/L NaOH
as solvent and a signal at 368 nm was taken. The HPLC method was
validated using Synergi Hydro-RP® C18 column (250x4.6 mm, 4 µm).
The mobile phase was constituted of methanol-water (61:39 v/v) with
pH adjusted to 2.5 with formic acid, at a flow rate of 1.0 mL/min. UV
detection was made at 375 nm. All analyses were performed with a
column temperature of 25 °C ± 1. The calibration curves were linear
over a concentration range from 4.0-24.0 µg/mL with a correlation
coefficient better than 0.9999. The detection limit (DL) and
quantitation limit (QL) were 0.25 µg/mL and 0.90 µg/mL for UV
method and 0.35 µg/mL and 1.20 µg/mL for HPLC method
respectively. The intra-day and inter-day precision expressed as RSD
were below 2% for both methods. The mean recovery of tenoxicam
was found to be in the range of 98.5-101.25% for UV method and
99.01-101.93% for HPLC method. The UV and HPLC methods were
found to be rapid, precise and accurate. Statistically there was no
significant difference between proposed UV spectrophotometric and
HPLC methods.
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INTRODUCTION
Tenoxicam (Figure 1) is an enolic acid derivative that
inhibits high levels of COX-2 at the sites of inflammation
and thus has anti-inflammatory, analgesic, and antipyretic
activity. This nonselective COX inhibitor is extensively
used in the treatment of rheumatoid arthritis and
osteoarthritis. Chemically, tenoxicam is 4-hydroxy-2-
methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-
carboxamide 1,1-dioxide with pKa 4.50 and 3.73.
To guarantee the pharmacological activity and assure
quality of pharmaceutical products it is important to quantify
them with accuracy and precision (UNITED States
Pharmacopeia, 2005). Several analytical methods are
described in recent literature such as mass spectrometric
(McKinney et al., 2004), spectrofluorometric (Taha et al.,
2002; Barary et al., 2004), potentiometric (El-Ries et al.,
2003), polarographic (Atkopar and Tuncel, 1996), infrared
spectrophotometric (Atay and Dincol, 1997) [7], coulometric
(Nikolic et al., 1993), spectrophotometric (Amin, 2002;
Garcia et al., 1999; El-Ries, 1998; Yener, Topaloglu, 1992;
El Walily et al., 1997), derivative spectrophotometric (Taha
et al., 2003) and high performance liquid chromatographic
techniques (Hye et al., 2005; Sultan, et al., 2005; Taha et al.,
2004; Bartsch et al., 2002; Abdel-Hamid, 2000; Joseph-
Charles and Bertucat, 1999; Radhofer-Welte, Dittrich, 1998;
Walily et al., 1997; Tracqui et al., 1995; Mason and Hobbs,
1995; Munera-Jaramillo, Botero-Garces, 1993; Carlucci et
al., 1992; Dixon et al., 1984).
The spectrophotometric method and HPLC with UV
detection are analytical techniques widely used in analytical
laboratories. The HPLC methods described in literature
involve sample pre-treatment and troublesome buffers
components in the mobile phase. The hyphenated LC-MS
detection makes these methods available to only a few. On
the other hand a majority of described spectrophotometric
methods involves sample pre-treatment or use of derivation
technique due to their application in the determination of the
active compound in the presence of its degradation
products. The objective of this study was to develop rapid
and economical methods that could be applied for
quantitative determination of tenoxicam in quality control
laboratories. The supporting data on repeatability,
recovery, linearity, specificity and limits of detection and
quantitation prove precision, accuracy, selectivity and
sensitivity of the proposed methods.
EXPERIMENTAL
Chemicals
The standard used was the pure compound (99.61 %)
and was used without any further purification. The samples
(A and B) were tablets containing 20 mg of tenoxicam. The
placebo was prepared in laboratory based on the excipients
present in tablet samples, namely microcrystalline cellulose,
starch, polyvidone, sodium croscarmelose, colloidal silicon
dioxide, macrogol 400, talc and titanium dioxide. The
standard, samples and excipients were obtained from local
pharmaceutical industries. HPLC grade methanol and
sodium hydroxide (NaOH) were obtained from Merck
(Darmstadt, Germany). High purity water was prepared by
using Waters Milli-Q® plus purification system.
Equipment
A LC system consisted of a solvent delivery system,
an auto-injector fitted with 20 µL loop, an online
degasification system, a column thermostat oven and an
UV/VIS photodiode array detector. The output signal was
monitored and integrated using CLASS VP® software
(Shimadzu Corporation, Japan).
The UV method was performed on a UV-VIS
spectrophotometer, UV-1601 (Shimadzu Corporation,
Japan). The output signal was monitored and processed
using UVPC v3.91 Personal Spectroscopy Software
(Shimadzu Scientific Instruments Inc. Japan).
Spectrophotometric condition
The UV method was performed with 0.1 mol/L
NaOH solution as medium. UV detections were made at
368 nm, using 1.0 cm quartz cell and with wavelength
scanning rate of 370 nm/min (250-450 nm).
Chromatographic condition
Analytical conditions were standardized through the LC
system using Synergi Hydro-RP® C18 column (250x4.6 mm,
FIGURE 1 - Chemical structure of tenoxicam.
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4 µm). The mobile phase was constituted of methanol-water
(61:39 v/v) with pH adjusted to 2.5 with formic acid, at a flow
rate of 1.0 mL/min. UV detection was made at 375 nm. The
volume of injection was fixed at 20 µL. All analyses were done
with a column temperature of 25°C ± 1. The mobile phase was
prepared fresh each day, vacuum-filtered through a 0.45 µm
Millipore® (HV) hydrophilic membrane.
Calibration curve (UV and HPLC)
The calibration curve for tenoxicam was constructed
by separate analyses (3 times) of six different standards
solutions of tenoxicam containing 4.0 to 24.0 µg/mL. The
solutions with desired concentrations were obtained by
diluting the stock solution with 0.1 mol/L NaOH (UV
method) and with mobile phase (HPLC method). The
calibration curve was constructed by plotting mean
response versus respective tenoxicam concentration.
Standard solution for determination of inter and
intra-day repeatability (UV and HPLC)
Amount of tenoxicam standard, equivalent to 12.0 mg
was accurately weighed and transferred to a 25 mL
volumetric flask. Approximately 20 mL of 0.1 mol/L NaOH
was added and the content of the flask was sonicated for
10 min. The solution in the flask was diluted to volume with
the same solvent. Appropriate dilutions were made with
0.1 mol/L NaOH to obtain solutions containing 12.0 µg/mL
of tenoxicam. For HPLC method, similar procedure was
adopted by using mobile phase as diluting solvent, to obtain
solution containing 12.0 µg/mL of tenoxicam.
Sample solution for determination of inter and intra-
day repeatability (UV and HPLC)
For the UV method, twenty tablets were individually
weighed and were triturated to obtain homogeneous mass.
Amount of sample mass, equivalent to 12.0 mg of tenoxicam,
was accurately weighed and transferred to a 25 mL volumetric
flask. Approximately 20 mL of 0.1 mol/L NaOH were added
and the content of the flask was sonicated for 10 min. The vo-
lume of the flask was completed with the same solvent and the
final solution was filtered through Whatmann no. 1 paper filter.
Appropriate dilutions were obtained by transferring aliquots
of the above solution to volumetric flasks. The final sample
solutions were obtained containing approximately 12.0 µg/mL
of tenoxicam. For HPLC method, similar procedure was
adopted by using mobile phase as diluting solvent, to obtain
final sample solutions containing approximately 12.0 µg/mL
of tenoxicam.
Standard and sample solutions for recovery test (UV
and HPLC)
For UV method, standard and sample solutions were
prepared separately as described above to obtain solution
containing 40.0 µg/mL of tenoxicam. Method accuracy
was assessed by determining the agreement between the
difference in the measured analyte concentrations of the
fortified and unfortified sample and the known amount of
analyte added to fortify the sample. Solution of standard
containing 40.0 µg/mL of tenoxicam, at three different
levels, was used to fortify the sample solutions. The final
concentrations of these fortified solutions were 8.0, 12.0
and 16.0 µg/mL of tenoxicam (Table III). The theoretical
concentrations of added standard in these solutions are 4.0,
8.0 and 12.0 µg/mL of tenoxicam, respectively.
For HPLC method, the recovery test was performed
with standard and sample solutions containing 40.0 µg/mL
of tenoxicam. The final concentrations of these fortified
solutions were 8.0, 12.0 and 16.0 µg/mL of tenoxicam
(Table III). All standard and sample solutions were filtered
through 0.45 µm, Millipore® (Millex HV) hydrophilic
membrane, before injection into the system.
RESULTS AND DISCUSSION
Quantitative determination of tenoxicam (UV)
The direct UV method allows a rapid and economical
quantification of tenoxicam in pharmaceutical preparations
without time-consuming sample pre-treatment steps.
Absorption spectra of the tenoxicam are shown in Figure
2. UV detection was carried out at 368 nm for the
quantification of tenoxicam.
FIGURE 2 - Ultraviolet absorption spectra in 0.1 NaOH:
(A) placebo, (B) 12.0 µg/mL tenoxicam standard, (C)
12.0 µg/mL tenoxicam (sample A) and (D) 12.0 µg/mL
tenoxicam (sample B).
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Quantitative determination of tenoxicam (HPLC)
To develop a suitable and robust LC method for the
determination of tenoxicam different mobile phases and
columns were employed to achieve the efficient separation
and resolution. Due to well known problems associated
with buffers our intention was to obtain rapid
chromatographic separation with good peak symmetry
without using a buffer solution. Attempts with traditional
reverse phase columns presented poor peak symmetry and
tailing problem. Most of the separation methods in
literature overcame these problems by use of buffers in
mobile phase. The proposed method was able to selectively
separate tenoxicam in a short chromatographic run
(4.5 min). The tenoxicam can be identified by matching the
UV spectrum and the retention times with standards. The
chromatograms are shown in Figure 3.
Linearity (UV and HPLC)
Linearity was checked by analyzing standard
solutions at six different concentration levels ranging from
4.0 to 24.0 µg/mL. The correlation coefficient was found
to be greater than 0.9999 for both the UV and HPLC
methods, indicating good linearity. The analytical curve
values of slope, intercept and correlation coefficient for
tenoxicam are presented in Table I.
Precision (UV and HPLC)
The method precision was evaluated by inter and
intra-day repeatability. The intra-day repeatability was
done by analyzing a single concentration of samples in
replicate (10 times) and is expressed in terms of RSD with
respective confidence interval. For UV method ten working
solutions (12.0 µg/mL) were prepared from same stock
solution, while for HPLC method single working solution
(12.0 µg/mL) was injected ten times. For both methods,
RSD values were found to be well below 1.52 %, indicating
good intra-day repeatability (Table II).
FIGURE 3 - Chromatograms of placebo, standard and
sample, concentration equivalent to 12.0 µg/mL, 20 µL
injected. Chromatographic conditions: mobile phase:
methanol-water (61:39 v/v), pH adjusted to 2.5 with formic
acid, flow rate 1.0 mL/min and UV detection at 375 nm;
Synergi Hydro-RP® C18 column (250x4.6 mm, 4 µm),
oven temperature (24 °C).
TABLE I - Linear regression data in the analysis of
tenoxicam using UV and HPLC methods
PARAMETERS UV HPLC
Concentration range (mg/mL) 4.0 – 24.0 4.0 – 24.0
Regression equation y = 0.0441x y = 67466x
+ 0.0117 + 15115
Correlation coefficient (r) 0.9999 0.9999
DL (mg/mL) 0.25 0.35
QL (mg/mL) 0.90 1.20
DL= Detection limit
QL= Quantitation limit
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The inter-day repeatability was determined by
analyzing sample solutions prepared from same stock
solution on three consecutive days, at the same
concentration level. The inter-day repeatability is expressed
in terms of RSD values with respective confidence interval.
The RSD values were well below 1.10 % indicates a good
intermediate precision for both methods (Table II).
Accuracy (UV and HPLC)
Standard addition for fortification and recovery
experiments were conducted to determine the accuracy of
the present method for the quantification of tenoxicam. As
per ICH guidelines the range of addition levels of impurities
used in this study is 70-130 % of the nominal concentration
(mean concentration of curve) (International Conference on
Harmonization, 1995). The accuracy of the method was
checked at three concentration levels i.e. at 8.0, 12.0 and
16.0 µg/mL. Triplicate analyses were done with HPLC
method and in case of UV method 10 determinations were
made. For both methods, recovery % calculations were
made based on the amount of standard added to the sample
solutions. The accuracy is expressed as percentage of
standard recovered from sample matrix with corresponding
RSD and confidence interval (AOAC International, 1990).
The mean recovery of tenoxicam was found to be in the
range of 98.5-101.25 % for UV method and 99.01-101.93
% for HPLC method. The recovery data is presented in
Table III.
Specificity (UV and HPLC)
Specificity is the ability of the method to accurately
measure the analyte response in the presence of all potential
sample components (excipients). All related excipients were
used to prepare placebo sample solution as described above
and were analyzed using proposed methods. The results
were compared with the analysis of a standard tenoxicam
TABLE II - Precision results and statistical data obtained in the determination of tenoxicam in pharmaceutical preparation
UV* HPLC*
Sample A Sample B Sample A Sample B
Intra-day
Day 1 19.80 ± 0.03 19.04 ± 0.05 20.20 ± 0.14 19.73 ± 0.15
RSD 0.25 0.37 0.99 1.07
Day 2 19.91 ± 0.21 18.83 ± 0.02 20.38 ± 0.12 20.03 ± 0.14
RSD 1.48 0.18 0.80 0.99
Day 3 20.35 ± 0.21 19.15 ± 0.17 20.86 ± 0.23 19.82 ± 0.16
RSD 1.49 1.27 1.52 1.11
Inter-day
20.02 ± 0.13 19.01 ± 0.05 20.48 ± 0.16 19.86 ± 0.15
RSD 0.93 0.60 1.10 1.06
*mean of 10 determinations
TABLE III - Results obtained in the recovery of tenoxicam standard solution added to sample A and sample B analyzed
by the proposed UV and HPLC methods
UV HPLC
Sample Amount (mg) Recovery Amount (mg) Recovery
Added Found (%) Added Found (%)
A 4.00 3.97 99.25 ± 0.13 4.00 3.98 99.55 ± 0.48
8.00 8.06 100.75 ± 0.14 8.00 7.96 99.51 ± 2.00
12.00 12.08 100.66 ± 0.06 12.00 12.23 101.93 ± 0.49
B 4.00 3.90 98.50 ± 0.33 4.00 3.96 99.01 ± 1.09
8.00 8.10 101.25 ± 0.69 8.00 7.96 99.52 ± 0.64
12.00 11.94 99.50 ± 0.25 12.00 11.93 99.47 ± 0.73
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solution. No interference from excipients was observed in
either of the proposed methods (Figure 2 and Figure 3).
Detection Limit (DL) and Quantitation limit (QL)
The DL and QL were determined for both HPLC and
UV methods. The limits were determined based on the
standard deviation amongst response and slope of the cur-
ve at lowest concentrations (International Conference on
Harmonization, 1995). The obtained theoretical values for
DL and QL were actually prepared and were cross checked
by actual analysis using proposed methods. The DL and QL
were 0.25 µg/mL and 0.90 µg/mL for UV method and
0.35 µg/mL and 1.20 µg/mL for HPLC methods
respectively (Table I).
Comparison between UV and HPLC method
The proposed analytical methods were compared
using statistical analysis. The F-test was applied to deter-
mine whether one population is more variable than another
in relative standard deviations (repeatability). The obtained
results were 1.20 and 1.36, for sample A and B,
respectively, well below the tabulated value (3.18) at 95%
confidence level. The t-test was applied to determine
whether or not there is a statistically significant difference
between the mean assay values of two proposed methods.
The obtained results were 0.23 and 0.38, for sample A and
B, respectively, well below the tabled value (2.10) at 95%
confidence level. The calculated F-values and t-values were
found to be less than the critical values at 5% significance
level (3.18 and 2.10 respectively).
CONCLUSION
The proposed methods for quantitative
determination of tenoxicam in pharmaceutical
formulation are efficient and sensitive. The studied
excipients of the commercial sample analyzed did not
interfere in the analysis, which proved the specificity of
the method for these formulations. Thus, the use of the
proposed methods in other type of formulations should be
made after a previous selectivity study. The UV and
HPLC methods were found to be simple, rapid, precise,
accurate and sensitive. The statistical data prove that the
two methods are equally precise and there is no significant
difference between the proposed methods for assay
determinations. Its advantages over other existing
methods are its low-cost and non-polluting conditions.
Either method can be used for routine quality control of
tenoxicam in commercial samples.
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RESUMO
Estudo comparativo de dois métodos rápidos e
sensíveis para a determinação quantitativa de
tenoxicam em comprimidos
Tenoxicam, um análogo de piroxicam, é um AINE
(Antiinflamatório Não-Esteróide). ë usado no tratamen-
to sintomático de doenças musculoesqueléticas das juntas,
tais como osteoartrite e artrite reumatóide, e, também, no
tratamento de danos dos tecidos moles. Sua determinação
quantitativa em formulações farmacêuticas é importante
para garantir os efeitos terapêuticos desejados. O obje-
tivo dessa pesquisa foi desenvolver, validar e comparar
métodos espectrofotométrico e cromatográfico na deter-
minação quantitativa de tenoxicam em comprimidos.
Neste trabalho, comprimidos contendo 20,0 mg de
tenoxicam de diferentes procedências foram analisados.
O método espectrofotométrico foi validado utilizando-se
0,1 mol/L de NaOH como solvente e se obteve sinal a 368
nm. O método por CLAE foi validado utilizando-se colu-
na Synergi Hydri-RP® C18 (250x4,6 nm, 4μm). A fase
móvel constitui-se de metanol-água (61:39 v/v), com pH
ajustado para 2,5 com ácido fórmico, e velocidade de flu-
xo de 1,0 mL/minuto. A detecção por UV foi efetuada a
375 nm. Todas as análises foram realizadas com tempe-
ratura de coluna a 25 oC ± 1. As curvas de calibração
foram lineares na faixa de concentração de 4,0 a 24,0 μg/
mL, comcoeficiente de correlação melhor que 0,9999. O
limite de detecção (LD) e o limite de quantificação (LQ)
foram 0,25 μg/mL e 0,90 μg/mL e 1,20 μg/mL por CLAE,
respectivamente. A precisão intra e inter-dia, expressa
como RSD, foi abaixo de 2% para ambos os métodos. A
média de recuperação do tenoxicam ficou na faixa de 98,5
a 101,25% para o método de UV, e 99,01 a 101,93, para
a CLAE. Os métodos de UV e de CLAE mostraram-se
rápidos, precisos e exatos. Estatisticamente, não se obser-
vou diferença significativa entre os métodos
espectrofotométricos (UV) e CLAE.
UNITERMOS: Tenoxicam/determinação quantitativa.
Espectrofotometria. Cromatografia a líquido de alta efi-
ciência.
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